Simtuzumab Preserves Cardiac Function in LMNA DCM 03/18/26
Welcome to Cardiology Today – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like cDPP3 and endovascular revascularization. Key takeaway: Simtuzumab Preserves Cardiac Function in LMNA DCM.
Article Links:
Article 1: cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies. (ESC heart failure)
Article 2: Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. (European journal of heart failure)
Article 3: Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy. (Circulation. Heart failure)
Article 4: Safety and Effectiveness of the Santreva™-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study. (The American journal of cardiology)
Article 5: Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/
📚 Featured Articles
Article 1: cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41834515
Summary: Circulating dipeptidyl peptidase 3 (cDPP3) is an established biomarker for cardiocirculatory failure, with elevated concentrations predicting poor patient outcomes in shock states. Researchers analyzed cDPP3 levels at baseline and follow-up in patients with acute heart failure enrolled in the STRONG-HF and CORTAHF trials. This investigation centered on the associations of cDPP3 with 180-day and 90-day outcomes, respectively. The evaluation of cDPP3 in acute heart failure provides crucial insights into the identification of prognostic indicators for improved risk stratification in this patient population.
Article 2: Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841702
Summary: V. C. Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. An implantable inferior vena cava (I. V. C.) sensor was utilized for 12 months in a congestion-guided management strategy for heart failure patients. Data from 65 patients in the FUTURE-HF and FUTURE-HF two trials, predominantly with New York Heart Association class three symptoms and Heart Failure with Reduced Ejection Fraction, were analyzed. Daily I. V. C. parameters were recorded, and adjudicated safety outcomes were assessed. This study demonstrates the application of continuous physiological monitoring to address the critical challenge of congestion in heart failure.
Article 3: Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841259
Summary: Simtuzumab attenuated Loxl2-mediated extracellular matrix remodeling and preserved cardiac function in dilated cardiomyopathy caused by LMNA mutations. This severe cardiac condition is marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, impairing left ventricular function and increasing heart failure risk. The findings identify simtuzumab as a therapeutic agent that addresses the pathogenesis of LMNA mutation-induced dilated cardiomyopathy. This represents a significant step towards developing targeted therapies for this specific genetic heart disease.
Article 4: Safety and Effectiveness of the Santreva™-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41571040
Summary: T. K. Endovascular Revascularization Catheter in the RESTOR-1 Peripheral C. T. O. Crossing Pivotal Study. The Santreva™-A. T. K. Endovascular Revascularization Catheter demonstrated its safety and effectiveness in the RESTOR-1 Peripheral Chronic Total Occlusion Crossing Pivotal Study. This prospective, multicenter trial included adult patients with Rutherford class two to five peripheral arterial disease and de novo femoropopliteal chronic total occlusions. The catheter successfully provided a mechanism for recanalization, addressing the challenges of traversing chronic total occlusions. This study establishes a new option for endovascular revascularization in complex peripheral arterial disease patients.
Article 5: Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41500397
Summary: Patients undergoing percutaneous coronary intervention (P. C. I.) were categorized for high bleeding risk (H. B. R.) and procedural complexity. High bleeding risk was defined by at least one major or two minor Academic Research Consortium H. B. R. criteria. Complex P. C. I. included treating three or more vessels or lesions, implanting three or more stents, or a total stent length over 60 millimeters. This study established concrete criteria for identifying patients with a dual burden of complex coronary anatomy and high bleeding risk, crucial for guiding individualized treatment strategies.
📝 Transcript
Today’s date is March 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Circulating Dipeptidyl Peptidase 3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies. Circulating dipeptidyl peptidase 3 (cDPP3) is an established biomarker for cardiocirculatory failure, with elevated concentrations predicting poor patient outcomes in shock states. Researchers analyzed cDPP3 levels at baseline and follow-up in patients with acute heart failure enrolled in the STRONG-HF and CORTAHF trials. This investigation centered on the associations of cDPP3 with 180-day and 90-day outcomes, respectively. The evaluation of cDPP3 in acute heart failure provides crucial insights into the identification of prognostic indicators for improved risk stratification in this patient population.
Article number two. Long-term Safety and Performance of an Implantable I. V. C. Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. An implantable inferior vena cava (I. V. C.) sensor was utilized for 12 months in a congestion-guided management strategy for heart failure patients. Data from 65 patients in the FUTURE-HF and FUTURE-HF two trials, predominantly with New York Heart Association class three symptoms and Heart Failure with Reduced Ejection Fraction, were analyzed. Daily I. V. C. parameters were recorded, and adjudicated safety outcomes were assessed. This study demonstrates the application of continuous physiological monitoring to address the critical challenge of congestion in heart failure.
Article number three. Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy. Simtuzumab attenuated Loxl2-mediated extracellular matrix remodeling and preserved cardiac function in dilated cardiomyopathy caused by LMNA mutations. This severe cardiac condition is marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, impairing left ventricular function and increasing heart failure risk. The findings identify simtuzumab as a therapeutic agent that addresses the pathogenesis of LMNA mutation-induced dilated cardiomyopathy. This represents a significant step towards developing targeted therapies for this specific genetic heart disease.
Article number four. Safety and Effectiveness of the Santreva™-A. T. K. Endovascular Revascularization Catheter in the RESTOR-1 Peripheral C. T. O. Crossing Pivotal Study. The Santreva™-A. T. K. Endovascular Revascularization Catheter demonstrated its safety and effectiveness in the RESTOR-1 Peripheral Chronic Total Occlusion Crossing Pivotal Study. This prospective, multicenter trial included adult patients with Rutherford class two to five peripheral arterial disease and de novo femoropopliteal chronic total occlusions. The catheter successfully provided a mechanism for recanalization, addressing the challenges of traversing chronic total occlusions. This study establishes a new option for endovascular revascularization in complex peripheral arterial disease patients.
Article number five. Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Patients undergoing percutaneous coronary intervention (P. C. I.) were categorized for high bleeding risk (H. B. R.) and procedural complexity. High bleeding risk was defined by at least one major or two minor Academic Research Consortium H. B. R. criteria. Complex P. C. I. included treating three or more vessels or lesions, implanting three or more stents, or a total stent length over 60 millimeters. This study established concrete criteria for identifying patients with a dual burden of complex coronary anatomy and high bleeding risk, crucial for guiding individualized treatment strategies.
Thank you for listening. Don’t forget to subscribe.
🔍 Keywords
cDPP3, endovascular revascularization, heart failure, congestion, device management, high bleeding risk, chronic total occlusion, cardiocirculatory failure, Simtuzumab, LMNA mutation, percutaneous coronary intervention, bleeding risk, inferior vena cava, risk stratification, implantable sensor, dilated cardiomyopathy, extracellular matrix remodeling, Santreva-ATK, cardiac function, acute heart failure, biomarker, peripheral arterial disease, complex coronary anatomy.
ℹ️ About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow